The Schazoo Pharmaceutical Laboratories (Pvt.) Ltd.
Private pharmaceutical manufacturer · Lahore · Pakistan
Long-established Lahore pharmaceutical manufacturer with manufacturing across tablets, capsules, liquids, injectables, eye drops and nasal sprays.
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Company type
- Private pharmaceutical manufacturer
- Address
- 71 B, C/2, Liberty Market, Gulberg III, Lahore, Pakistan
- Website
- schazoo-spl.com ↗
- Phone
- +92 42 35760882-4
- hr@schazoo-spl.com
- Official contact
- Contact page ↗
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 100%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| – D3 | Cholecalciferol | 5 mg | Injection | 1ml x 5 | 065834 | PKR 1,586.70 | PKR 317.34/mL | 70% above median |
| – D3 | Cholecalciferol | 5 mg | Injection | 1ml x 1's | 065834 | PKR 330.57 | PKR 330.57/mL | 77% above median |
| Alvry | Ibuprofen + Pseudoephedrine | 200 mg + 30 mg | Tablet | 10 x 10 | 087562 | PKR 446.33 | PKR 4.46/tablet | 20% above median |
| Alvry | Ibuprofen | 100 mg/5 mL | Suspension | 90 ml | 094641 | PKR 106.41 | PKR 1.18/mL | 25% above median |
| Alvry | Ibuprofen + Pseudoephedrine | 100 mg + 15 mg/5 mL | Suspension | 120 ml | 094641 | PKR 139.50 | PKR 1.16/mL | 26% above median |
| Alvry Forte | Ibuprofen + Pseudoephedrine | 400 mg + 60 mg | Tablet | 10 x 10 | 087563 | PKR 587.28 | PKR 5.87/tablet | No comparator |
| Angiorex | Enoxaparin | 60 mg/0.6 mL | Prefilled syringe injection | 1’s | 062543 | PKR 701.38 | PKR 701.38/syringe | No comparator |
| Angiorex | Enoxaparin | 60 mg | Injection | 1’s | 062543 | PKR 701.38 | PKR 701.38/vial/unit | 20% above median |
| Angiorex | Enoxaparin | 40 mg/0.4 mL | Prefilled syringe injection | 1’s | 062544 | PKR 540.16 | PKR 540.16/syringe | No comparator |
| Angiorex | Enoxaparin | 40 mg | Injection | 1’s | 062544 | PKR 540.16 | PKR 540.16/vial/unit | 22% above median |
| Angiorex | Enoxaparin | 20 mg/0.2 mL | Prefilled syringe injection | 1’s | 062545 | PKR 314.05 | PKR 314.05/syringe | No comparator |
| Angiorex | Enoxaparin | 20 mg | Injection | 1’s | 062545 | PKR 314.05 | PKR 314.05/vial/unit | 12% below median |
| Artemex | Artemether | 80 mg | Injection | 6 x 1 ml | 042986 | PKR 1,239.07 | PKR 206.51/mL | 17% above median |
| Artemex-L | Artemether + Lumefantrine | 20 mg + 120 mg | Tablet | 2 x 8's | 048096 | PKR 660.84 | PKR 41.30/tablet | 5% above median |
| Atrac | Atracurium besylate | 10 mg | Injection | 2.5ml x 5’s | 042987 | PKR 1,159.13 | PKR 92.73/mL | No comparator |
| Atrac | Atracurium besylate | 10 mg/mL | Injection | 5ml x 5’s | 042988 | PKR 1,459.48 | PKR 58.38/mL | 12% below median |
| Avitone | Vitamin A | 50,000 IU | Tablet | 3 x 10 | 000831 | PKR 23.82 | PKR 0.79/tablet | No comparator |
| Babyrhinocol Pholcodiene ., ChlorphenireamineSource observed | Ephedrine | 1.5 mg | Syrup | 120 ml | 002200Official source ↗ | No indexed price | — | — |
| Babyrhinocol Syrup Pholcodiene 1.5 mg., Chlorphenireamine 1 mg., Ephedrine 5 mg., Paracetamol 80mg/ml,Source observed | — | — | — | 120 ml | 002200Official source ↗ | No indexed price | — | — |
| Beconazole | Fluconazole | 150 mg | Capsule | 1’s | 071106 | PKR 284.98 | PKR 284.98/capsule | 8% above median |
| Bilagol L | Lactulose | 3.75 g/5 mL | Syrup | 120 ml | 024229 | PKR 305.64 | PKR 2.55/mL | No comparator |
| Ceretek | Haloperidol | 5 mg/1 mL | Injection | 1 ml x 25's | 077583 | PKR 364.13 | PKR 14.57/mL | No comparator |
| Ceretek | Haloperidol | 5 mg | Injection | 1 ml x 25's | 077583 | PKR 364.13 | PKR 14.57/mL | 45% above median |
| Cinox | Ciprofloxacin | 250 mg | Tablet | 10's | 065828 | PKR 259.29 | PKR 25.93/tablet | Near median |
| Cinox | Ciprofloxacin | 750 mg | Tablet | 10's | 065829 | PKR 411.97 | PKR 41.20/tablet | Near median |
| Cinox | Ciprofloxacin | 500 mg | Tablet | 10's | 065831 | PKR 428.82 | PKR 42.88/tablet | Near median |
| Cinox | Ciprofloxacin | 3 mg/mL | Otic drops | 5 ml. | 092606 | PKR 184.42 | — | No comparator |
| Cinox-D | Ciprofloxacin + Dexamethasone | 3 mg/mL + 1 mg/mL | Otic drops | 5 ml. | 092607 | PKR 214.75 | — | No comparator |
| Clonil | Clomipramine | 10 mg | Tablet | 10 x 10 | 042799 | PKR 351.14 | PKR 3.51/tablet | Near median |
| Clonil | Clomipramine | 25 mg | Tablet | 20's | 042800 | PKR 330.42 | PKR 16.52/tablet | 107% above median |
| DeCalc Plus | Calcium carbonate | 1250 mg | Chewable tablet | 3 x 10 | 013085 | PKR 183.77 | PKR 6.13/tablet | No comparator |
| Eficaz | Cefixime | 400 mg | Capsule | 5's | 069408 | PKR 563.10 | PKR 112.62/capsule | Near median |
| Eficaz Dry | Cefixime | 100 mg/5 mL | Dry suspension | 30 ml | 071432 | PKR 314.24 | PKR 10.47/mL | Near median |
| Femistar | Paracetamol | 500 mg | Tablet | 4 x 10's | 062795 | PKR 851.30 | PKR 21.28/tablet | 488% above median |
| Femistar Max | Paracetamol | 250 mg | Tablet | 4 x 10’s | 069077 | PKR 851.30 | PKR 21.28/tablet | No comparator |
| Floxac | Fluoxetine | 20 mg | Capsule | 1 x 10's | 036646 | PKR 134.24 | PKR 13.42/capsule | Near median |
| Floxac | Fluoxetine | 20 mg/5 mL | Oral solution | 60 ml | 036647 | PKR 206.75 | PKR 3.45/mL | No comparator |
| Floxac | Fluoxetine | 20 mg | Tablet | 10's | 045997 | PKR 134.24 | PKR 13.42/tablet | 7% above median |
| Flupexin Injections | Fluphenazine decanoate | 25 mg/mL | Injection | 5ml x 1's | 065849 | PKR 151.35 | PKR 30.27/mL | 75% below median |
| Foierin | Ribavirin | 500 mg | Tablet | 1 x 10's | 085874 | PKR 205.98 | PKR 20.60/tablet | Near median |
| Foierin | Ribavirin | 400 mg | Tablet | 3 x 10's | 086359 | PKR 506.95 | PKR 16.90/tablet | 6% below median |
| Foierin | Ribavirin | 400 mg | Tablet | 1 x 10's | 086359 | PKR 183.24 | PKR 18.32/tablet | Near median |
| Foierin | Ribavirin | 600 mg | Tablet | 1 x 10's | 086360 | PKR 244.33 | PKR 24.43/tablet | Near median |
| Foschlor | Chloroquine | 250 mg | Tablet | 500's | 106093 | PKR 579.27 | PKR 1.16/tablet | 26% below median |
| Kofnil | Paracetamol + Pseudoephedrine + Chlorpheniramine | 30 mg + 2 mg + 300 mg | Tablet | 10 x 10 | 012528 | PKR 82.89 | PKR 0.83/tablet | No comparator |
| L Flox | Levofloxacin | 0.5% | Ophthalmic drops | 5 ml | 050298 | PKR 152.70 | PKR 30.54/mL | 18% above median |
| Lamprene | Lamotrigine = | 5 mg | Tablet | 3 x 10 | 042920 | PKR 129.37 | PKR 4.31/tablet | 33% above median |
| Lamprene | Lamotrigine = | 25 mg | Tablet | 3 x 10 | 042921 | PKR 648.65 | PKR 21.62/tablet | Near median |
| Lamprene | Lamotrigine = | 50 mg | Tablet | 3 x 10 | 042922 | PKR 864.88 | PKR 28.83/tablet | Near median |
| Lamprene | Lamotrigine = | 100 mg | Tablet | 3 x 10 | 042923 | PKR 1,081.10 | PKR 36.04/tablet | Near median |
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.